Hyalolex is IGC’s lead cannabis-based supplement for treating and managing Alzheimer’s patients.
“The cannabis market is showing explosive growth and we are aggressively moving forward with our vision of owning and marketing the leading brands for large medical indications such as Alzheimer’s, Parkinson’s, PTSD, pain, veterinary medicine and cancer. With 8 patents filed, IGC has made significant strides towards achieving these goals and building value for our shareholders as a NYSE American listed company,” stated Ram Mukunda, CEO of IGC.
“California is considered to be the largest addressable U.S. market for cannabis with an environment that strongly embraces its acceptance. This represents a significant opportunity for Hyalolex and our brands, as such we are currently coordinating the necessary steps to efficiently and rapidly introduce our product to high-density regions in the state. It should be noted that according to U.S. Census data, California has an estimated population of 39.54 million and that total is larger than all of Canada,” continued Mukunda.
IGC’s management team has been actively meeting with California-based manufacturers and distributers to assemble the requisite combination of partners to efficiently bring Hyalolex to dispensaries, patients and caregivers in California. Our “Drops of Clarity” marketing program will highlight the potential benefits of Hyalolex as a supplement to cannabis physicians as well as to caregivers and patients via both a digital format and through grassroots outreach.
About IGC
IGC has two lines of business, a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry that address transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA). The company is based in Maryland, USA.
Our website: www.hyalolex.com Twitter @IGCIR
About Alzheimer’s disease
Alzheimer’s disease (AD) is a form of dementia. It is known as America’s most expensive disease, with an estimated cost to the U.S. economy of $236 billion. AD currently affects more than 5.3 million Americans and over 66% of AD patients are women.
Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2018, and in other reports filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180814005222/en/
Contacts
India Globalization Capital, Inc.
Claudia Grimaldi, 301-983-0998
Source: India Globalization Capital, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20180814005222/en
